Valeant to Borrow About $7 Billion for Bausch & Lomb Buyout

Valeant Pharmaceuticals International Inc. (VRX) said it secured debt financing from Goldman Sachs Group Inc. for $6.7 billion to $7.2 billion for its buyout of Bausch & Lomb Holdings Inc. Montreal-based Valeant will pay $4.5 billion for the eye-care company and spend $4.2 billion to repay Bausch & Lomb’s debt, the companies said in a statement. The deal will bring Valeant’s debt as a ratio of earnings before interest, taxes, depreciation and amortization to 4.6 times, according to the statement.

To contact the editor responsible for this story: Cecile Gutscher at cgutscher@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.